Semax
Recherche publiée et base de preuves
Semax is a synthetic heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro, consisting of the ACTH(4-7) fragment extended with a C-terminal Pro-Gly-Pro tripeptide that confers resistance to enzymatic degradation. It lacks corticotropic activity and is registered in Russia for ischaemic stroke, optic nerve disease and cognitive indications. Its best-characterised actions are regulation of BDNF and NGF expression and broad transcriptomic modulation of inflammatory and neurosignalling genes in rodent cerebral ischaemia models. Human evidence is dominated by Russian clinical studies of stroke and optic neuropathy, with two small placebo-controlled fMRI studies in healthy volunteers; no regulatory-grade Western trial exists.
- Semax est un peptide synthétique dérivé d'un fragment d'ACTH, approuvé en Russie.
- Des études humaines ont rapporté des bénéfices chez les patients atteints d'AVC.
- Aucun grand essai contrôlé par placebo aux normes occidentales n'existe.
39 études · 13 depuis 2023 · plus récente 2026
- Études citées
- 39
- Publiées 2023+
- 13
- Article le plus récent
- 2026
- Dernière révision
- oct. 2026
Thèmes récurrents dans la littérature
- ACTH(4-10) analogue
- melanocortin
- BDNF and NGF expression
- ischaemic stroke neuroprotection
- transcriptomic modulation
- copper and amyloid interaction
- intranasal nootropic
- default mode network
Identifiants du composé
- CAS
- 80714-61-0
- PubChem
- 9811102
Recommandé par un comité consultatif de la FDA.
Le 23–24 July 2026, le comité consultatif sur la préparation pharmaceutique de la FDA a examiné Semax pour la liste 503A Bulks et a recommandé son ajout lors d'un vote rapporté de 8–5 with one abstention. Heard on the second day of the meeting and recommended on a divided vote.
Ce n'est pas une approbation. Le comité conseille ; il ne décide pas. La recommandation n'est pas contraignante, la FDA n'a pas terminé la réglementation qui changerait formellement quoi que ce soit, et l'inclusion dans la liste 503A Bulks n'équivaut pas à l'approbation FDA d'un médicament. La liste régit également la préparation pharmaceutique pour les patients, qui est une activité distincte de la fourniture à usage de recherche uniquement.
Ce que le vote consultatif de juillet 2026 a réellement accompli décrit le processus, les autres composés examinés et les quatre choses que le vote est régulièrement mal interprété comme signifiant.
Ce qu'est Semax, chimiquement.
- Formule moléculaire
- C37H51N9O10S
- Masse moléculaire
- 813.9 g/mol
- Numéro CAS
- 80714-61-0
- PubChem CID
- 9811102
Ces chiffres proviennent de la fiche PubChem pour ce composé et décrivent la base libre. Le peptide lyophilisé est normalement fourni sous forme de sel d'acétate ou de trifluoroacétate et contient de l'eau résiduelle, donc la masse de poudre dans un flacon ne correspond pas à la quantité suggérée par la masse moléculaire ci-dessus. La pureté chromatographique sur un certificat d'analyse ne résout pas cette différence non plus — comment lire un certificat d'analyse explique pourquoi.
39 études publiées.
Classées par rigueur du protocole d'étude, puis par date. Chaque entrée renvoie à sa source pour que les résultats puissent être vérifiés dans l'article plutôt que pris sur parole.
- 01Clinique humaine2026· Russian (English abstract)
[Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome].
Sheludchenko VM, et al. · Vestn Oftalmol · comparative study, n=42 patients (42 eyes) after vitrectomy for macula-off rhegmatogenous retinal detachment; heliox plus endonasal Semax electrophoresis (n=23) vs Semax nasal drops (n=19), 12-month follow-up
By month 6 the combined-physiotherapy group showed greater recovery of best-corrected visual acuity and fundus microperimetry parameters than the Semax-drops group. Both groups received Semax, so the study compared treatment packages rather than Semax against no Semax.
- 02Clinique humaine2026
Increasing Direct-to-Consumer Use of Semax and Selank Peptides Decoded from LLM-Curated Clinical Notes and Physician Adjudication
Marwaha A, et al. · Preprints.org · retrospective electronic-health-record study (preprint, not peer reviewed) using LLM-curated clinical notes with physician adjudication; Semax use confirmed in 22 of 43 patients with note mentions, pooled Semax or Selank cohort n=49
Documented use of both peptides rose from 2024, most often for cognitive enhancement or mood, anxiety and stress support (28.6% each), with intranasal use common (37%) and stacking with other peptides in 33 patients (67%). Notes recorded patient-reported positive responses in 16 of 49 patients and safety concerns or adverse-event sentiments in 13 of 49; the authors state the study was not designed to evaluate effectiveness or harm.
Résultat de sécurité signalé. Manual review found isolated dyspnea, palpitations, flushing and emergency department visits during periods overlapping reported Semax or Selank use (n<11).
- 03Clinique humaine2025· Russian (English abstract)
Study of the effectiveness of the drug «Semax» in the complex treatment of non-proliferative diabetic retinopathy
TSDI – Tashkent State Dental Institute, et al. · MTO · controlled three-group study, n=87 patients (174 eyes) with type 2 diabetes and mild or moderate non-proliferative diabetic retinopathy; traditional treatment vs two main groups taking calcium dobesilate and Semax
After traditional treatment the control group showed negative changes in OCT-angiography, ocular blood flow, BDNF and VEGF measures, while these parameters rose above baseline in patients taking calcium dobesilate and Semax. The abstract does not separate the effect of Semax from that of calcium dobesilate.
- 04Clinique humaine2022· Russian (English abstract)
The effect of neuropeptide ACTH4-10 on the adaptation of patients to dental prostheses according to the data of monitoring the emotional state using a polygraph
Pozhilova EV, et al. · Rev Clin Pharm Drug Ther · controlled three-group study in patients receiving their first complete removable dentures; intranasal Semax vs intranasal saline vs no pharmacological correction, emotional state monitored by polygraph
Patients given intranasal Semax reached the polygraph values of adapted patients on most indicators within the first weeks after fitting and on all indicators a month after fitting, which was not seen in the saline or untreated groups. The abstract does not give group sizes.
- 05Clinique humaine2022· Russian (English abstract)
[Results of the application of complex physiotherapeutic neurostimulation in optical neuropathies of various genesis].
Dragon AK, et al. · Vopr Kurortol Fizioter Lech Fiz Kult · controlled study, n=60 patients (120 eyes) with optic neuropathy of vascular origin, mean age 66.2; multi-component neurostimulation including endonasal Semax electrophoresis (n=30) vs vitamin therapy (n=30), 24 weeks of follow-up
Therapeutic efficacy in the neurostimulation group was 94% one week, 88% at 12 weeks and 83% at 24 weeks after treatment, against no more than 30-42% in the control group. Semax was one part of a package that also included transcranial magnetic and electrical stimulation, oxybaric therapy and acupuncture, so its own contribution cannot be separated.
- 06Clinique humaine2022· Russian (English abstract)
Complex ophthalmic neurostimulation in the rehabilitation of patients with glaucomatous optic neuropathy
FSBSI Research Institute of Eye Diseases, Moscow, FSBSI Petrovsky National Research Centre of Surgery, Moscow, et al. · Physiotherapist · controlled study in stage 1 primary open-angle glaucoma: extended neurostimulation including endonasal Semax electrophoresis (42 patients) vs magnetic stimulation plus Semax electrophoresis (36 patients) vs no physiotherapy (38 patients), up to 48 weeks
The extended complex produced the most pronounced results (fewer relative scotomas, lower electrical perceptual threshold, higher PERG P50 amplitude, thicker ganglion cell complex), mostly persisting up to 48 weeks; the magnetic stimulation plus Semax group improved less, with the greatest effect up to 24 weeks, and controls showed only a positive trend lasting no more than 12 weeks. Semax was delivered within physiotherapy packages, so its separate effect cannot be determined.
- 07Clinique humaine2022· Russian (English abstract)
Application of pharmaco-physiotherapeutic technologies to improve local light sensitivity in inflammatory optic neuropathy
FSBSI Research Institute of Eye Diseases, Moscow, et al. · Physiotherapist · controlled three-group study, n=71 patients (142 eyes) with inflammatory optic neuropathy: extended neurostimulation including endonasal Semax electrophoresis (n=23) vs magnetic-electrical stimulation plus Semax electrophoresis (n=24) vs vitamin-based basic therapy (n=24), up to 48 weeks
The extended complex gave larger and more lasting gains in light-sensitivity thresholds in both eyes throughout the 48-week follow-up, while the stimulation plus Semax electrophoresis group improved significantly only in the worse eye, for up to 24 weeks. Semax was part of combined physiotherapy, so its own effect cannot be separated.
- 08Clinique humaine2020
Functional Connectomic Approach to Studying Selank and Semax Effects
Panikratova YR, et al. · Doklady Biological Sciences · placebo-controlled resting-state fMRI, 52 healthy participants scanned before and 5 and 20 min after Semax, Selank or placebo
Semax and Selank produced distinguishable changes in resting-state functional connectivity between the right amygdala and right temporal cortex relative to placebo.
- 09Clinique humaine2019· Russian (English abstract)
Characteristics of emotional state and cognitive processes in patients with ischemic stroke in acute period
Kotsyubinskaya YV, et al. · Medicinskij alfavit · observational clinical study, n=25 patients in the acute period of ischaemic stroke; emotional state and cognitive testing
The study mainly described anxiety, depression and memory in acute stroke; the abstract states only that an improvement was noted after treatment with Semax, without effect sizes or a control group.
- 10Clinique humaine2018
Effects of Semax on the Default Mode Network of the Brain
Lebedeva IS, et al. · Bulletin of Experimental Biology and Medicine · placebo-controlled resting-state fMRI, 24 healthy volunteers aged 43.9 +/- 9.5 years; intranasal 1% Semax (n=14) vs placebo (n=10)
The Semax group showed a greater volume of the rostral (medial frontal cortex) subcomponent of the default mode network than controls, demonstrating a measurable acute central effect after intranasal dosing.
- 11Clinique humaine2018· Russian (English abstract)
[The efficacy of semax in the tretament of patients at different stages of ischemic stroke]
Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · clinical trial, n=110 post-ischaemic-stroke patients stratified into early (89 +/- 9 days) and late (214 +/- 22 days) rehabilitation with and without Semax 6000 mcg/day for two 10-day courses
Semax administration raised plasma BDNF levels irrespective of rehabilitation timing and was associated with faster improvement and better final Barthel index scores. The trial was not placebo-controlled.
- 12Clinique humaine2015· Russian (English abstract)
[POSSIBLE DRUG CORRECTION OF LIPID METABOLISM DISTURBANCES ASSOCIATED WITH METABOLIC SYNDROME IN PATIENTS WITH PSORIASIS].
Dontsova EV · Eksp Klin Farmakol · controlled comparative study in patients with psoriasis and metabolic syndrome; conventional therapy (n=58) vs conventional therapy plus intranasal Semax (n=60)
Adding Semax was associated with falls in initially elevated serum total cholesterol, triglycerides and LDL cholesterol and a rise in initially low HDL cholesterol, whereas conventional therapy alone produced no statistically significant change in these lipids.
- 13Clinique humaine2014· Russian (English abstract)
The results of Semax neuroprotective efficacy investigation
Strakhov VV, et al. · Ophthalmology Reports · controlled study, n=36 patients (72 eyes) with primary open-angle glaucoma; Semax added to intraocular-pressure-lowering therapy (n=24) vs pressure-lowering therapy alone (n=12), 1 month
After one month, Heidelberg tomography, perimetry and corneal confocal microscopy showed no negative change in the optic nerve head, the corneal subbasal nerve plexus or the visual field in the Semax group. No adverse reactions to Semax were observed; the abstract reports no between-group efficacy comparison.
- 14Clinique humaine2013· Russian (English abstract)
[The results of the application of the pre-formed physical factors and neuroprotective therapy for the rehabilitative treatment of the patients with diabetic retinopathy].
Nazarova GA, et al. · Vopr Kurortol Fizioter Lech Fiz Kult · comparative three-group study, n=114 patients (228 eyes) aged 42 to 70 with diabetes and non-proliferative diabetic retinopathy; endonasal Semax electrophoresis vs intranasal Semax drops vs standard therapy without Semax
Both Semax groups showed improvement in visual, perimetric and electrophysiological measures, with the most pronounced and longest-lasting effect (up to 12 months) in the endonasal electrophoresis group.
- 15Clinique humaine2012· Russian (English abstract)
[Research of medical properties of the preparation "Semaks" at rehabilitation of veterans of extra risk divisions].
Puchkvoa EI, Alishev NV · Adv Gerontol · comparative clinical study during rehabilitation of veterans of special-risk units (liquidators of radiation accidents on nuclear submarines)
The authors reported positive effects of Semax on cerebral haemodynamics, cardiac function on standard ECG and Holter monitoring, and mental performance. The abstract gives no patient numbers, comparator details or effect sizes.
- 16Clinique humaine2007· Russian (English abstract)
[The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]
Serdiuk AV, Levitskii GN, Miasoedov NF, Skvortsova VI · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · open-label trial, n=27 patients with motor neuron disease; intranasal 1% Semax 12 mg/day in two 10-day courses, serial needle EMG and ALS scales
Semax did not influence the course of chronic partial denervation or clinical ALS ratings, but significantly improved total quality-of-life score via emotional state and motivation, peaking at day 10.
- 17Clinique humaine2005· Russian
[Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency].
Gusev EI, et al. · Zh Nevrol Psikhiatr Im S S Korsakova · comparative clinical study, n=187 patients with cerebrovascular insufficiency
Semax treatment was associated with clinical improvement, stabilisation of disease progression and fewer strokes and transient ischaemic attacks during follow-up, with a low rate of side effects including in older patients.
- 18Clinique humaine2002
Therapy of peptic ulcer with semax peptide.
Ivanikov IO, et al. · Bull Exp Biol Med · controlled clinical study in patients with refractory peptic ulcers; intranasal Semax added to standard antiulcer drugs vs standard drugs alone
On day 14 of treatment, ulcer healing was observed in 89.5% of patients receiving intranasal Semax versus 30.8% in the control group. The authors called for further clinical studies; group sizes are not given in the abstract.
- 19Clinique humaine2001· Russian (English abstract)
[Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone].
Kurysheva NI, et al. · Vestn Oftalmol · comparative clinical study in glaucoma patients with normalised intraocular pressure; neuroprotective therapy including Semax vs traditional neuroprotective treatment
Electrophysiological and computer-based examinations were reported to show advantages of the Semax-containing regimen over traditional neuroprotective treatment. The English abstract gives no patient numbers or effect sizes.
- 20Clinique humaine2000· Russian (English abstract)
[Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease]
Polunin GS, Nurieva SM, Baiandin DL, Sheremet NL, Andreeva LA · Vestnik oftalmologii · controlled clinical trial in vascular, toxic-allergic and inflammatory optic nerve disease and partial optic atrophy; intranasal drops vs endonasal electrophoresis vs control
Addition of Semax to standard therapy was associated with improved visual acuity, enlarged total visual field, increased electrical sensitivity and conductivity of the optic nerve, and improved colour vision.
- 21Clinique humaine1999· Russian (English abstract)
[Use of semax at a follow-up of patients with posthypoxic encephalopathy].
Alekseeva GV, et al. · Anesteziol Reanimatol · comparative clinical study, n=73 patients with remote posthypoxic encephalopathy (14 in persistent vegetative state)
Semax was effective in patients with memory disorders, and in some cases EEG showed episodes of paroxysmal activity after injection, leading the authors to recommend EEG monitoring at the first injection.
Résultat de sécurité signalé. Paroxysmal EEG activity was recorded after Semax injection in some patients with posthypoxic brain injury.
- 22Clinique humaine1999· Russian (English abstract)
[Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke].
Miasoedova NF, et al. · Zh Nevrol Psikhiatr Im S S Korsakova · retrospective comparative clinical and immunobiochemical study, patients in the acute period of ischaemic stroke treated with Semax
Semax treatment was associated with a shift in the balance of mediators toward those the authors classed as anti-inflammatory (interleukin-10, tumour necrosis factor-alpha) over factors maintaining inflammation (interleukin-8, C-reactive protein). The abstract gives no patient numbers.
- 23Clinique humaine1997· Russian (English abstract)
[Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]
Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibat'ko VN, Zhuravleva EIu, Vanichkin AV · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · controlled clinical trial, 30 patients with acute hemispheric ischaemic stroke vs 80 conventionally treated controls; EEG mapping and somatosensory evoked potentials
Adding Semax to intensive therapy was associated with faster regression of general cerebral and focal, especially motor, deficits. Effective daily doses were reported as 12 mg for moderate and 18 mg for severe strokes.
- 24Clinique humaine1996
Synthetic acth analogue semax displays nootropic-like activity in humans
Kaplan AYA, et al. · Neurosci. Res. Comm. · human study of Semax in Neuroscience Research Communications; design and sample size not available in the registry record
The title reports nootropic-like activity of Semax in humans. Results are not available in the abstract (the registry record has no abstract).
- 25Clinique humaine1996· Russian
[Effect of the heptapeptide Semax on the human electroencephalogram].
Koroleva MV, et al. · Biull Eksp Biol Med · human electroencephalography study of Semax; design and sample size not available in the registry record
The title reports effects of the heptapeptide Semax on the human electroencephalogram. Results are not available in the abstract (PubMed holds no abstract).
- 26Clinique humaine1994· Russian (English abstract)
Pharmacologic correction of psychic processes by «semax» medicine during rehabilitation period of neurosurgical patients
Prilukova TI, et al. · Neurology bulletin · clinical study in neurosurgical patients during postoperative and post-traumatic rehabilitation, short Semax course
Semax was reported to improve learning, auditory perception, the volume of verbal and affective material memorised, and long-term and some kinds of short-term memory even after short-term (5-day) treatment. The abstract gives no patient numbers or control group.
- 27Animal in vivo2025
The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease
Radchenko AI, et al. · Acta Naturae · transgenic APPswe/PS1dE9/Blg mice; open field, novel object recognition and Barnes maze plus histology
Semax and a derivative improved performance on novel object recognition and Barnes maze tests and reduced the number of amyloid inclusions in cortex and hippocampus.
- 28Animal in vivo2025
Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice
Liu R, et al. · British Journal of Pharmacology · T9-T10 contusion spinal cord injury in female C57BL/6 mice, plus PC12 neuroinflammation model; RNA-seq, network pharmacology and molecular docking
Semax improved functional recovery and inhibited lysosomal-membrane-permeabilisation-related pyroptosis, acting via USP18 regulation; docking and pharmacology analyses identified the mu-opioid receptor as a candidate target. This is one of the few non-Russian primary Semax studies.
- 29Animal in vivo2025
Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage
Filippenkov IB, et al. · International Journal of Molecular Sciences · rat transient middle cerebral artery occlusion (tMCAO), RNA-seq of striatum and frontal cortex at 24 h
Semax and ACTH(6-9)PGP normalised ischaemia-disrupted expression profiles for hundreds of genes in the striatum, with fewer differentially expressed genes than in the frontal cortex, indicating region-dependent transcriptomic effects.
- 30Animal in vivo2024
ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke
Filippenkov IB, et al. · Biomedicines · rat tMCAO model, whole-transcriptome sequencing of frontal cortex 24 h post-stroke
ACTH-like peptides including Semax partially compensated ischaemia-induced disturbance of the brain gene expression profile at 24 h, affecting neurotransmitter and inflammatory gene sets.
- 31Animal in vivo2024
Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress
Inozemtseva LS, et al. · European Journal of Pharmacology · male Sprague-Dawley rats, chronic unpredictable stress; daily intraperitoneal Semax or Melanotan II at 60 nmol/kg
Semax reversed or attenuated stress-induced anhedonia, suppression of body-weight gain, adrenal hypertrophy and reduced hippocampal BDNF. No effect was seen on forced swim test immobility.
- 32Animal in vivo2024
Changes of Transcriptomic Activity in Rat Brain Cells under the Influence of Synthetic Adrenocorticotropic Hormone-Like Peptides
Filippenkov IB, et al. · Biochemistry (Moscow) · rat brain cells, transcriptomic profiling under ACTH-like peptide administration
Synthetic ACTH-like peptides including Semax produced measurable shifts in brain cell transcriptomic activity, extending the group's stroke-model transcriptomics to non-ischaemic conditions.
- 33Animal in vivo2023
Synthetic Adrenocorticotropic Peptides Modulate the Expression Pattern of Immune Genes in Rat Brain following the Early Post-Stroke Period
Filippenkov IB, et al. · Genes · rat tMCAO model, RNA-seq of dorsolateral frontal cortex 4.5 h after occlusion
Semax was associated with 131 differentially expressed genes and ACTH(6-9)PGP with 322 at 4.5 h post-stroke; both partially prevented ischaemia-induced changes in immune- and neurosignalling-related expression profiles.
- 34Animal in vivo2010
Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action
Shadrina M, et al. · Journal of Molecular Neuroscience · rat hippocampus, frontal cortex and retina; time-course of NGF and BDNF gene expression after Semax
Semax produced region- and time-dependent changes in NGF and BDNF gene expression, establishing the neurotrophin-induction mechanism most often cited for the compound.
- 35Animal in vivo2006· Russian (English abstract)
[Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration].
Shevchenko KV, et al. · Bioorg Khim · rats, intranasal tritium-labelled Semax, brain and blood radioactivity kinetics
Two minutes after intranasal administration 0.093% of the administered radioactivity per gram was found in brain, about 80% of it as intact Semax; the peptide was rapidly degraded, with the tripeptide Pro-Gly-Pro predominating among metabolites.
- 36In vitro2025
The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons
Kolbaev SN, et al. · Bulletin of Experimental Biology and Medicine · rat hippocampal and cerebellar slices, calcium imaging; Semax 1 microM
Semax increased the frequency of spontaneous intracellular calcium fluctuations in CA1 pyramidal-layer cells but did not affect proton-stimulated calcium entry in cerebellar granule cells, arguing against acid-sensing ion channels as the primary neuroprotective mechanism.
- 37In vitro2025
Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing
Tomasello MF, et al. · Bioinorganic Chemistry and Applications · cell-free and cell-based assays of Cu(II)-amyloid beta redox chemistry and cytotoxicity
Semax stripped Cu(II) from amyloid beta and silenced its redox activity, reducing catalysed reactive oxygen species production and associated cytotoxicity in vitro.
- 38In vitro2023
Synthetic corticotropins and the GABA-receptor system: Direct and delayed effects
Vyunova TV, et al. · Chemical Biology & Drug Design · isolated rat brain plasma membranes plus systemic administration in an acute restraint stress rat model; [3H]GABA binding
Semax and related synthetic corticotropins each altered [3H]GABA binding differently at high- and low-affinity sites. Acute restraint stress reduced binding at the low-affinity site, and peptide pre-administration did not prevent this stress effect.
- 39In vitro2022
Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models
Sciacca MFM, et al. · ACS Chemical Neuroscience · artificial membrane models of copper-induced amyloid beta aggregation
Semax modified copper-induced amyloid beta aggregation and amyloid formation at model membranes, supporting a metal-coordination component to its reported neuroprotective chemistry.
Ce que ces preuves n'établissent pas.
Russian marketing authorisation was granted on the basis of domestic trials that were largely open-label or actively controlled rather than double-blind and placebo-controlled; no Semax trial has been registered or completed under EMA or FDA standards. Effects on cognition in healthy adults are supported only by two small fMRI studies with surrogate imaging endpoints, and no dose-ranging, pharmacokinetic or long-term safety data are available in Western populations.
Questions courantes sur la recherche.
- What is Semax?
Semax is a synthetic heptapeptide made from the ACTH(4-7) fragment extended with Pro-Gly-Pro. It was developed in Russia in the 1980s and is studied primarily in neurotrophic-signalling and cerebral-ischaemia research. It carries none of the hormonal corticotropic activity of full-length ACTH.
- What does the research literature actually describe?
Rodent studies report increases in brain-derived neurotrophic factor protein and changes in BDNF and trkB expression, plus broad transcriptome shifts in ischaemia-reperfusion models. A Russian clinical literature examines intranasal courses in ischaemic stroke. These are research findings in defined study settings, not established outcomes, and nothing here is a claim about what the compound does for a person.
- How does Semax differ from Selank?
Both share the Pro-Gly-Pro stabilising tail and both came out of the same Russian research programme, but their active fragments differ. Semax derives from ACTH(4-7) and is studied in neurotrophic and ischaemia models; Selank derives from the immune tetrapeptide tuftsin and is studied in anxiety and stress models.
Disponible dans notre catalogue
À des fins de recherche uniquement. Non destiné à la consommation humaine, au diagnostic, au traitement ou à la prévention de toute condition. Rien sur cette page ne constitue un avis médical, et aucune étude résumée ici ne doit être considérée comme une recommandation.